Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | GOT1 | P17174 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491 | 0.85 | HPGDS (0.64) | EPHX2TRPV1 | |
| SCHEMBL13148292 | 0.85 | KMT2A (0.56) | TRPV1CYP2C19FAAH | |
| SCHEMBL6538866 | 0.78 | EPHX2 (0.67) | EPHX2CYP2C9CYP2C19 | |
| SCHEMBL4558228 | 0.77 | EPHX2 (0.91) | EPHX2TRPV1CYP2C9CYP2C19ACHE | |
| SCHEMBL15170992 | 0.76 | EPHX2 (0.73) | EPHX2 | |
| SCHEMBL13873283 | 0.76 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19ACHE | |
| SCHEMBL4393722 | 0.74 | EPHX2 (0.75) | EPHX2TRPV1CYP2C9CYP2C19GOT1 | |
| SCHEMBL20236394 | 0.74 | EPHX2 (0.75) | EPHX2TRPV1CYP2C9CYP2C19FAAH | |
| SCHEMBL13634099 | 0.74 | EPHX2 (0.75) | EPHX2CYP2C9CYP2C19 | |
| SCHEMBL7532176 | 0.73 | EPHX2 (0.70) | EPHX2TRPV1CYP2C9CYP2C19GOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | EPHX2 381/4885TRPV1 137/4885CYP2C9 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.